Development of treatment and prevention for pancreatic neuroendocrine tumor using glucagon gene knock-out mouse

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10049
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: Nagoya University
• Principal Investigator: Kikumori Toyone 名古屋大学, 医学部附属病院, 講師 (90402635)
• Co-Investigator(Renkei-kenkyūsha): Hayashi Yoshitaka 名古屋大学, 環境医学研究所, 准教授 (80420363)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 膵内分泌腫瘍 / グルカゴン / mTOR阻害剤

Outline of Final Research Achievements

We explored treatment / prevention methods by clarifying pathologically and molecular biologically the biological properties of tumor developed in glucagon gene knockout mouse in which pancreatic tumors arose spontaneously. We reported that the pancreatic tumor developed in this mouse closely resembles histological and biological attitudes to human pancreatic neuroendocrine tumor (pNET). Expression of cellular growth factors and angiogenic factors (AKT, mTOR, VEGF, etc.) in pancreatic islet cells at each stage of the process of malignant transformation were examined by immunostaining of excised tissue specimens. Everolimus, an mTOR inhibitor which has clinical indication for pNET, was continued to be administered to these mice shortly after birth, and it was confirmed that pancreatic tumor development was suppressed.

Free Research Field

内分泌外科